Tag: Asthma

Clinical Trials, Research and Development

FDA puts hold on Rapt trials of drug for eczema, asthma

February 20, 2024

Via: Biopharma Dive

Analysts have followed Rapt as they view its drug, an oral pill dubbed zelnecirnon, as a possible competitor to Dupixent in conditions like eczema. Dupixent, which was developed by Sanofi and Regeneron, is a multibillion-dollar product approved for a range […]

FDA, Regulations

FDA Expands Use of Asthma Med Xolair to Treat Food Allergies

February 16, 2024


People threatened by accidental exposure to foods they’re allergic to may have a new weapon of defense: On Friday, the U.S. Food and Drug Administration expanded the use of the asthma drug Xolair to help prevent anaphylactic reactions. Xolair (omalizumab) […]

FDA, Regulations

AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma

January 11, 2023

Via: Biopharma Dive

Airsupra is part of a growing portfolio of new drugs that are helping offset wilting sales of older AstraZeneca respiratory medicines such as Pulmicort. It’s an essential therapeutic area for the British drugmaker; in the third quarter, respiratory and immunology […]

Clinical Trials, FDA, Regulations, Research and Development

FDA panel backs AZ’s PT027 asthma rescue drug, but in adults only

November 9, 2022

Via: Pharmaphorum

PT027 is based on beta agonist albuterol and corticosteroid budesonide – two well-established therapies – combined into a fixed-dose inhaler that can be used as rescue medication when a patient with asthma is in the throes of an attack. The […]

Clinical Trials, Research and Development

Study Probes Links Between Vaccines and Asthma in Kids, With Inconclusive Results

September 28, 2022


Aluminum in childhood vaccines has long been the cause of speculation about a potential link to allergies and asthma, but a new study designed to figure out whether there might be a connection did not come to a definitive conclusion. […]

Clinical Trials, Research and Development

Amgen, AstraZeneca dig into data from phase 3 asthma trial, emerging with evidence of efficacy in hard-to-treat subgroup

September 7, 2021

Via: FierceBiotech

Piece by piece, Amgen and AstraZeneca are building the case for their potential asthma blockbuster. The latest brick to fall into place comes from a new slice of phase 3 data, which suggests tezepelumab may be particularly effective in a […]

FDA, Regulations

FDA Accepts Dupixent (dupilumab) for Review in Children with Moderate-to-severe Asthma

March 4, 2021

Via: BioSpace

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on treatment for children aged 6 to 11 […]